Burning Rock Biotech Ltd(BNR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,583 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
BNR Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Burning Rock Biotech Ltd (BNR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BNR at 27.4/100 on a 32-signal composite quality model, placing it at rank #2,583 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Burning Rock Biotech Ltd reports quarterly revenue of $77.2M, net income of $-7.9M, an operating margin of -10.2%. Top institutional holders of BNR by reported 13-F value include Kynam Capital Management, CRCM, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. BNR trades on the Nasdaq exchange and files with the SEC under CIK 1792267. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Burning Rock Biotech Ltd directly from SEC EDGAR. Burning Rock Biotech Ltd's 13F Pro composite quality score has ranged between 23 and 29 since 2026, currently 27.4 — an improving long-term trajectory across 47 quarterly and live scoring snapshots.
Revenue
FY 2025
$77.2M
Net Income
FY 2025
$-7.9M
Free Cash Flow
FY 2025
$-4.8M
Operating Margin
FY 2025
-10.2%
ROIC
FY 2025
-10.2%
D/E Ratio
FY 2025
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-85.0% YoYNet Income
+97.7% YoYOperating Income
+97.8% YoYTotal Assets
-86.7% YoYTotal Debt
Op. Cash Flow
+69.2% YoYFree Cash Flow
+70.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $77.2M -85.0% | $515.8M -4.0% | $537.4M -4.6% | $563.2M +10.9% | $507.9M +18.1% | $429.9M |
| Net Income | $-7.9M +97.7% | $-346.6M +47.0% | $-653.7M +32.7% | $-971.2M -21.9% | $-796.7M -95.6% | $-407.2M |
| Operating Income | $-7.8M +97.8% | $-357.6M +46.6% | $-669.3M +31.7% | $-980.4M -23.0% | $-797.1M -93.3% | $-412.4M |
| Total Assets | $117.3M -86.7% | $885.3M -14.9% | $1.04B -34.5% | $1.59B -30.3% | $2.28B -14.4% | $2.66B |
| Total Debt | $1.7M | $0.00 | — | $0.00 -100.0% | $372.0K -91.6% | $4.4M |
| Operating Cash Flow | $-28.4M +69.2% | $-92.3M +63.9% | $-255.8M +44.0% | $-456.8M +4.4% | $-477.9M -549.8% | $-73.5M |
| Free Cash Flow | $-29.2M +70.1% | $-97.7M +63.0% | $-263.9M +49.1% | $-518.8M +23.9% | $-682.2M -409.8% | $-133.8M |
Get alerted when BNR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Burning Rock Biotech Ltd including:
Top Institutional Holders of BNR
Kynam Capital Management, LP
$10.5M1,238,563 shCRCM LP
$1.8M211,997 shRENAISSANCE TECHNOLOGIES LLC
$442.3K52,838 shMORGAN STANLEY
$364.9K43,594 shNikko Asset Management Americas, Inc.
$257.7K29,724 shSumitomo Mitsui Trust Holdings, Inc.
$248.8K29,724 shBANK OF AMERICA CORP /DE/
$244.1K29,164 shCITADEL ADVISORS LLC
$236.6K27,288 shSC CHINA HOLDING Ltd
$177.5K21,212 shUBS Group AG
$150.0K17,916 sh
| Fund | Value | Shares |
|---|---|---|
| Kynam Capital Management, LP | $10.5M | 1,238,563 |
| CRCM LP | $1.8M | 211,997 |
| RENAISSANCE TECHNOLOGIES LLC | $442.3K | 52,838 |
| MORGAN STANLEY | $364.9K | 43,594 |
| Nikko Asset Management Americas, Inc. | $257.7K | 29,724 |
| Sumitomo Mitsui Trust Holdings, Inc. | $248.8K | 29,724 |
| BANK OF AMERICA CORP /DE/ | $244.1K | 29,164 |
| CITADEL ADVISORS LLC | $236.6K | 27,288 |
| SC CHINA HOLDING Ltd | $177.5K | 21,212 |
| UBS Group AG | $150.0K | 17,916 |
Companies Similar to BNR
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Inogen Inc
TH International Ltd
Inotiv, Inc.
AVANOS MEDICAL, INC.
Prelude Therapeutics Inc
ANGIODYNAMICS INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BNR on your watchlist
Track score changes the day Burning Rock Biotech Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BNR a good stock to buy?
13F Pro's AI-powered analysis of Burning Rock Biotech Ltd (BNR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BNR are available on the BNR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BNR is classified as a small company.
Which hedge funds own BNR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BNR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Burning Rock Biotech Ltd's investment landscape.